TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06163430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TERN-701
Description: TERN-701 orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TERN-701
Description: TERN-701 orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TERN-701
Description: TERN-701 orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TERN-701
Description: TERN-701 orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TERN-701
Description: TERN-701 orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TERN-701
Description: TERN-701 orally QD
Study: NCT05053867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Description: Inhaled

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Standard of Care
Study: NCT06541210

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT06127199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ovaprene
Description: Non-hormonal intravaginal ring
Study: NCT06534905

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette
Description: Each participant assigned to the e-cigarette group will given a rechargeable NJOY Ace e-cigarette that is either tobacco or mint-flavored (based on their preference). Participants will also be given disposable pods prefilled with nicotine. When the pod is empty, the participant will throw it away and replace it with a new pod provided by the study staff. Participants will be asked to use as little or as much of the e-cigarette during their study participation, including choosing not to use the product. Participants will also be given information on the relative harms of nicotine and tobacco products as recommended by the American Society of Addiction Medicine.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control/Standard Advice
Description: Brief advice to quit according recommendations from the American Society of Addiction Medicine
Study: NCT04310020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study: NCT04752150

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Analgesia management; group ESPB and RIB
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Analgesia management; group ESPB and RIB
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
Study: NCT04310020

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05828810

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidne Gluconate-Alcohol Skin Preparation
Description: Participants will undergo skin antisepsis with 4% chlorhexidine gluconate pre-wash, followed by 2% chlorhexidine gluconate with 70% isopropyl alcohol skin preparation.~The surgical field to be sterilized will be at the discretion of the surgical team, but typically includes the distal torso to ankle for patients undergoing hip arthroplasty and proximal thigh to ankle for patients undergoing knee arthroplasty.~Pre-wash of the surgical area will be carried out using a wet chlorhexidine surgical scrub brush followed by immediate drying using towels. The definitive preparation will then be carried out using tinted chlorhexidine gluconate-alcohol sponges applied with forceps. The drying time and the minimum number of sponge packs used will comply with the product 'Instructions for Use'. The drapes can be applied as per the surgeon's usual approach and they will be treated according to the institution and surgeon's routine practice for draping and surgical site infection prevention.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Poviodine-iodine Skin Preparation
Description: Participants will undergo skin antisepsis with 7.5% povidone-iodine detergent pre-wash, followed by 10% povidone-iodine skin preparation.~The surgical field to be sterilized will be at the discretion of the surgical team, but typically includes the distal torso to ankle for patients undergoing hip arthroplasty and proximal thigh to ankle for patients undergoing knee arthroplasty.~Pre-wash of the surgical area will be carried out using iodine detergent soaked gauze pads followed by immediate drying using towels. The definitive preparation will then be carried out using povidone-iodine soaked gauze pads applied with forceps. The drapes can be applied as per the surgical team's usual approach and they otherwise will be treated according to the institution and surgeon's routine practice for draping and surgical site infection prevention.
Study: NCT05856591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Resources & Kitchen Skills (FoRKS)
Description: Food Resources \& Kitchen Skills (FoRKS) includes 5 weeks of hypertension classes followed by 11 weeks of home-delivered Mediterranean-style ingredient kits and virtual cooking classes with embedded lessons in kitchen organization, tool use, nutrition, budgeting, and shopping.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: Enhanced Usual Care (EUC) includes 5 weeks of hypertension classes.
Study: NCT06096038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cyclophosphamide 300 mg/meter square IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: fludarabine 30 mg/meter square IV × 3 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell Therapy
Description: the autologous T lymphocyte chimeric antigen receptor cells against the CSPG4 antigen iC9-CAR.CSPG4 T cell infusion iC9-CAR.CSPG4 T cell infusion
Study: NCT06162221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-6291
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-6236
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-6236
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-6236
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV Infusion
Study: NCT06043089

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice supplementation or placebo
Description: Athletes received 7 days of beetroot juice supplementation with nitrate supplementation (2 × 70 mL of beetroot juice ∼12.9 mmol NO3-; Beet It, James White Drinks, Ipswich, UK) or placebo (2 × 70 mL of water with beetroot powder with negligible nitrate content).
Study: NCT05842603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac Lifestyle Program
Description: 12-week, tailored nutrition and physical activity program comprised of virtual and in-person classes.
Study: NCT06162221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Infusion
Study: NCT05288959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Session 2: Single-pulse TMS (spTMS)
Description: Uni-focal TMS (MagVenture, Farum, Denmark) is delivered to one brain area while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. The targeted brain areas and TMS intensities may vary across runs. An MRI-based TMS navigation system (Localite, Bonn, Germany) is used to navigate the TMS coil.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sessions 3 - 5: Paired associative stimulation (PAS)
Description: During each PAS run, bi-focal TMS (MagVenture, Farum, Denmark) is delivered to two brain areas while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. The asynchronies between the two TMS coils are kept constant within each session but differ across sessions. Within each session, to observe PAS effects on connectivity, uni-focal spTMS is delivered to the stimulated areas before and after the PAS modulation while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. In addition, resting-state EEG/EMG and a behavioral measure (bimanual task coordination) are recorded before and after the PAS modulation. An MRI-based TMS navigation system (Localite, Bonn, Germany) is used to navigate the TMS coils.
Study: NCT06475248

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Technique
Description: For the technique performed in the control group, the researcher will come into contact with the volunteers' chests. This contact will be maintained for the same period of time as the experimental group (6 minutes).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching technique
Description: Stretching technique for the upper trapezius and sternocleidomastoid: the volunteer will be in supine position on the couch, the researcher will perform the technique from the contralateral side of the muscle to be treated, the hand will contact the ipsilateral shoulder to stabilize, meanwhile, with the other hand, contact the upper trapezius and perform a rhythmic pull in contralateral rotation. This technique is performed bilaterally.
Study: NCT06162221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-9805
Description: Oral Tablet
Study: NCT05705258

Intervention type: DRUG
Intervention: Aflibercept (Eylea, BAY86-5321)
Description: Treatment with Intravitreal (IVT)-AFL must be made by the treating ophthalmologist
Study: NCT06075095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI HFO 320/14.4/9.6μg
Description: Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI HFO 320/14.4/9.6μg
Description: Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI HFO 320/14.4/9.6μg
Description: Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI HFO 320/14.4/9.6μg
Description: Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI HFO 320/14.4/9.6μg
Description: Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI HFO 320/14.4/9.6μg
Description: Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI HFA 320/14.4/9.6 μg
Description: Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart):

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI HFA 320/14.4/9.6 μg
Description: Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart):

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI HFA 320/14.4/9.6 μg
Description: Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart):

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI HFA 320/14.4/9.6 μg
Description: Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart):

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI HFA 320/14.4/9.6 μg
Description: Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart):
Study: NCT05691088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paracetamol injection
Description: Patients were randomized to receive either paracetamol during mechanical ventilation. When patients were randomized to receive paracetamol (40 mg/kg per day in 4 doses), a placebo infusion of normal saline was administered continuously at the same rate as an equivalent infusion. Placebos could not be distinguished from the active study drug in color, odor, or viscosity.~In both study groups, IMV was maintained with sufentanil (0-0.2 mcg/kg/h), propofol (0-4 mg/kg/h), and dexmedetomidine (0-1 mcg/kg/h). Assessment of sedation levels by the bedside nurse using the FLACC pain scale to determine if the child is adequately comfortable or in need of more or less medication to maintain adequate ventilation. Assessment of sedation levels by the bedside nurse using the FLACC pain scale (every 6 hours as a minimum time interval).
Study: NCT06075095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI HFA 320/14.4/9.6 μg
Description: Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart):

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo MDI HFA
Description: Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo MDI HFA
Description: Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo MDI HFA
Description: Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo MDI HFA
Description: Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo MDI HFA
Description: Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo MDI HFA
Description: Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)
Study: NCT05600543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumbar belt
Description: All subjects (LBP group and healthy group) wear the belt during the two visits to perform differents tests.~The invistigator will ask the LBP patients to wear the lumbar belt between the two visits (for 4 weeks, for 4 to 8 hours per day)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lombaskin lumbar belt and the Lyne Up percko postural T-shirt.
Description: Lombaskin lumbar belt and the Lyne Up percko postural T-shirt could be worn during the third addtional visit proposed to the healthy subject.
Study: NCT06112002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend an educational session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Receive educational materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05456555

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flapless with Enamel Matrix Derivatives (EMD)
Description: Experimental sites will receive a closed non-surgical treatment with a combined use of minicurettes and ultrasonic instruments with thin and delicate tips. Teeth will be instrumented until no residual calculus could be detected. A visualization of the root surface will be accomplished under magnification by using dental loups 4.0X. In the test group, the roots will be conditioned with 24% ethylenediaminetetraacetic acid (EDTA) for 2 minutes. After rinsing with sterile saline, enamel matrix derivatives (EMD) will be applied on the dried root surface.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flapless without Enamel Matrix Derivatives (EMD)
Description: Experimental sites will receive a closed non-surgical treatment with a combined use of minicurettes and ultrasonic instruments with thin and delicate tips. Teeth will be instrumented until no residual calculus could be detected. A visualization of the root surface will be accomplished under magnification by using dental loups 4.0X. No adjunct will be administered.
Study: NCT05005312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: PK Boosting agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: PK Boosting agent
Study: NCT05083182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab will be administered as subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered as subcutaneous injection.
Study: NCT06043089

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot juice supplementation or placebo
Description: Athletes received 7 days of beetroot juice supplementation with nitrate supplementation (2 × 70 mL of beetroot juice ∼12.9 mmol NO3-; Beet It, James White Drinks, Ipswich, UK) or placebo (2 × 70 mL of water with beetroot powder with negligible nitrate content).
Study: NCT05608889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Total Worker Health Mindfulness Enhanced Program
Description: The intervention will be delivered during 12, 45-minute weekly meetings of Correctional Professionals while on shift. Those sessions will be a combination of a video, mindfulness activity, and a group learning activity. It will conclude with members stating personal goals that will be followed up at the next meeting.~Sessions will be scripted to make them easy to implement with high fidelity, and include tasks, learning activities, and wrap-up with practice instructions for each week. Coworkers will be responsible for running the sessions, which promotes shared norms and social support.
Study: NCT06475248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhibition of the suboccipital
Description: Inhibition of the suboccipital: the participant is in the supine position, the researcher will position himself behind the patients head. In this technique, contacts will be made on the suboccipital area with the 2nd, 3rd and 4th fingers of both hands. Make a slight pull with your body backwards and wait that there is relaxation of muscular tensions.
Study: NCT06455540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superior hypogastric plexus block
Description: Prior to the laparoscopic hysterectomy and any additional procedures, the superior hypogastric plexus block will be performed on all the patients. The block will contain 20 mL of 0.75% ropivacaine hydrochloride or 0.9% normal saline. The injection will be performed by tenting the presacral peritoneum, aspirating with a laparoscopic needle-tip syringe to ensure extravascular placement, and injecting the block.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Superior hypogastric plexus block
Description: Prior to the laparoscopic hysterectomy and any additional procedures, the superior hypogastric plexus block will be performed on all the patients. The block will contain 20 mL of 0.75% ropivacaine hydrochloride or 0.9% normal saline. The injection will be performed by tenting the presacral peritoneum, aspirating with a laparoscopic needle-tip syringe to ensure extravascular placement, and injecting the block.
Study: NCT06500169

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete golf related exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear activity tracker

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Examination
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recreational Therapy
Description: Participate in golf program